Literature DB >> 12967519

Evidence-based management of thrombosis in the antiphospholipid antibody syndrome.

Michelle Petri1.   

Abstract

Recommendations for the management of thrombosis in the antiphospholipid antibody syndrome have been based largely on retrospective case series. Several clinical trials have been recently published on the management of thrombosis in general. Two clinical trials have specifically addressed thrombosis in antiphospholipid antibody syndrome, and one is underway. These new clinical trials have challenged the previous dogma of a target International Normalized Ratio of 3 to 4 ("high-intensity" warfarin).

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12967519     DOI： 10.1007/s11926-003-0023-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  22 in total

1.  Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.

Authors:  Emily Somers; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients.

Authors:  N M Shah; M A Khamashta; T Atsumi; G R Hughes
Journal:  Lupus       Date:  1998       Impact factor: 2.911

3.  Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis.

Authors:  Hermine I Brunner; Wee-Shian Chan; Jeffrey S Ginsberg; Brian M Feldman
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

4.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

5.  Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.

Authors:  M H Rosove; P M Brewer
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

6.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Authors:  Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn
Journal:  N Engl J Med       Date:  2003-02-24       Impact factor: 91.245

7.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.

Authors:  O Vaarala; M Mänttäri; V Manninen; L Tenkanen; M Puurunen; K Aho; T Palosuo
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

Review 8.  The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

Authors:  D J Wallace; M Linker-Israeli; A L Metzger; V J Stecher
Journal:  Lupus       Date:  1993-02       Impact factor: 2.911

9.  Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.

Authors:  R H Derksen; P G de Groot; L Kater; H K Nieuwenhuis
Journal:  Ann Rheum Dis       Date:  1993-09       Impact factor: 19.103

10.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245
View more
  5 in total

1.  Complement system on the attack in autoimmunity.

Authors:  John P Atkinson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 2.  Treatment of the antiphospholipid antibody syndrome.

Authors:  Christopher Wu; Kenneth Kalunian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

3.  High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study.

Authors:  Anna Broder; Jonathan N Tobin; Chaim Putterman
Journal:  J Clin Pathol       Date:  2012-03-03       Impact factor: 3.411

4.  Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.

Authors:  Tunde Tarr; Gabriella Lakos; Harjit Pal Bhattoa; Pal Soltesz; Yehuda Shoenfeld; Gyula Szegedi; Emese Kiss
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 5.  Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety.

Authors:  Nahid A Qushmaq; Samar A Al-Emadi
Journal:  ISRN Rheumatol       Date:  2014-04-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.